Former GlaxoSmithKline CEO and R&D Boss Secure New Gigs at Biotech VC Firms

  • Post author:
  • Post category:BioPharma

<IMG SRC"http://enewsletters.biospace.com/images/news/biospace-news-815x450-investor.jpg" NAME"Former GlaxoSmithKline CEO and R&D Boss Secure New Gigs at Biotech VC Firms" ALT"Former GlaxoSmithKline CEO and R&D Boss Secure New Gigs at Biotech VC Firms"September 19, 2017By…

Continue ReadingFormer GlaxoSmithKline CEO and R&D Boss Secure New Gigs at Biotech VC Firms

Biotech Startup Bonanza Continues as Emerges With $30 Million

  • Post author:
  • Post category:BioPharma

<IMG SRC"http://enewsletters.biospace.com/images/news/biospace-news-815x450-stocks4.jpg" NAME"Biotech Startup Bonanza Continues as Disarm Therapeutics Emerges With $30 Million" ALT"Biotech Startup Bonanza Continues as Disarm Therapeutics Emerges With $30 Million"September 19, 2017By Mark Terry, BioSpace... Source:…

Continue ReadingBiotech Startup Bonanza Continues as Emerges With $30 Million

<b>Kaleido Biosciences</b> Emerges From Stealth Mode With $65 Million and Will be Helmed by Fomer Cubist Exec

  • Post author:
  • Post category:BioPharma

<IMG SRC"http://enewsletters.biospace.com/images/news/biospace-news-815x450-investor.jpg" NAME"Kaleido Biosciences Emerges From Stealth Mode With $65 Million and Will be Helmed by Former Cubist Exec" ALT"Kaleido Biosciences Emerges From Stealth Mode With $65 Million and Will…

Continue Reading<b>Kaleido Biosciences</b> Emerges From Stealth Mode With $65 Million and Will be Helmed by Fomer Cubist Exec

Bay Area's Ultragenyx Swoops in With $138 Million Bid for Almost-Sold Dimension Therapeutics

  • Post author:
  • Post category:BioPharma

<IMG SRC"http://enewsletters.biospace.com/images/news/biospace-news-815x450-stocks4.jpg" NAME"Bay Area's Ultragenyx Swoops in With $138 Million Bid for Almost-Sold Dimension Therapeutics" ALT"Bay Area's Ultragenyx Swoops in With $138 Million Bid for Almost-Sold Dimension Therapeutics"September 18, 2017By…

Continue ReadingBay Area's Ultragenyx Swoops in With $138 Million Bid for Almost-Sold Dimension Therapeutics